Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Atopix Therapeutics
Oxford, England, United Kingdomatopixtherapeutics.co.uk ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Atopix Therapeutics developed oral CRTH2 antagonists for allergic and eosinophilic diseases, with its lead candidate timapiprant showing efficacy in asthma and allergic rhinoconjunctivitis in over 800 patients and demonstrating an excellent safety profile. The company focused on Th2-mediated eosinophilic asthma, targeting the CRTH2 receptor to interfere with allergic inflammation without broad immunosuppression.
- Therapeutic areas
- ImmunologyInfectious DiseasesDermatologyPulmonology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Atopix Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atopix Therapeutics.